Company intelligence / Profile preview

GlobeStar Therapeutics Corporation

Richland, Washington, United Statesmarketscreener.com ↗

Ownership: Private
Development stage: Preclinical

Overview

GlobeStar is developing Project Amethyst™, a patented combination therapy using minocycline, fluconazole, and atorvastatin—each previously FDA-approved for other uses—to target neurodegeneration in MS. The company has completed pre-clinical work and is planning pharmacokinetic studies as the next step toward human clinical trials. No published clinical efficacy results yet[1][5][6].

Therapeutic areas: Neurology
Modalities: Drug repurposing (combination of small molecules/minimally modified approved drugs)
Industry: Biotech

Drug pipeline

1 asset

Project Amethyst

Unknown

Partnerships

Collaborations with CROs in Europe and India for trial design/execution[6]

Beyond the preview

Go deeper on GlobeStar Therapeutics Corporation.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GlobeStar Therapeutics Corporation.

Explore the full profile